HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares saw an uptick in trading volume on Wednesday . 116,959 shares changed hands during trading, a decline of 3% from the previous session's volume of 120,456 shares.The stock last traded at $16.41 and had previously closed at $16.68.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HCM. StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research note on Wednesday, March 27th. Cantor Fitzgerald restated an "overweight" rating on shares of HUTCHMED in a research report on Friday, January 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $29.70.

HUTCHMED Trading Down 1.4 %

The firm's 50-day simple moving average is $15.99 and its two-hundred day simple moving average is $16.75. The company has a current ratio of 2.72, a quick ratio of 2.60 and a debt-to-equity ratio of 0.06.

Institutional Trading of HUTCHMED

Several large investors have recently modified their holdings of HCM. Goldman Sachs Group Inc. grew its position in shares of HUTCHMED by 1,096.7% in the second quarter. Goldman Sachs Group Inc. now owns 3,913,287 shares of the company's stock valued at $49,464,000 after purchasing an additional 3,586,271 shares during the last quarter. Bellevue Group AG grew its position in shares of HUTCHMED by 62.6% in the first quarter. Bellevue Group AG now owns 1,750,690 shares of the company's stock valued at $33,123,000 after purchasing an additional 673,820 shares during the last quarter. Millennium Management LLC grew its position in shares of HUTCHMED by 141.0% in the fourth quarter. Millennium Management LLC now owns 870,022 shares of the company's stock valued at $12,859,000 after purchasing an additional 508,959 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of HUTCHMED in the second quarter valued at approximately $5,266,000. Finally, Jane Street Group LLC grew its position in shares of HUTCHMED by 450.0% in the fourth quarter. Jane Street Group LLC now owns 391,802 shares of the company's stock valued at $5,791,000 after purchasing an additional 320,568 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.